-
The role of high in normal-1 (HIN-1) as a potential biomarker in combating glioblastoma is being described for the first time in this study.
-
Tumor-adjacent tissues showed higher methylation status of RASSF1A, HIN-1 and MGMT promoters.
-
SCGB3A1-183 T and SCGB3A1 IVS1-189 A alleles might have a protective effect against nasal polyposis.
-
aberrant HIN-1 promoter methylation could be an independent and important biomarker used in predicting the prognosis and progression of breast cancer
-
Methylation of HIN-1 promoter is a novel epigenetic biomarker associated with poor outcomes in OCCA patients.
-
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancers was associated with clinical characteristics, but only RASSF1A methylation was associated with time to first recurrence and overall survival.
-
HIN1, was the most "dietary sensitive" genes, as methylation of their promoters was associated with intakes of at least two out of the eight dietary methyl factors examined.
-
analysis of AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer
-
Data show that SCGB3A1 was down-regulated in invasive compared with DCIS, whereas talin 2 (TLN2) and PTGS1 were up-regulated in invasive compared with DCIS.
-
Data suggest that high methylation of the HIN-1 promoter results in silenced HIN-1 expression in gastric cancer, and that 5-aza-2'-deoxycytidine reverses HIN-1 methylation and reduces viability of gastric cancer cells.
-
The methylation levels and frequencies of HIN1, RASSF1A and TWIST, and average MR were significantly lower in basal-like subtype compared to luminal or human epithelial growth factor receptor-2 subtype.
-
Hypermethylation of HIN-1 is associated with lymphatic metastasis of breast cancers.
-
HIN-1, RAR-beta, RASSF1A, and Twist had the ability to distinguish high-grade squamous intraepithelial lesions/squamous cell carcinomas from low-grade squamous intraepithelial lesions/negative cervical scrapings
-
Sporadic breast tumors with a "BRCA1-like" histopathological phenotype also demonstrated significantly lower frequency of HIN-1 promoter methylation.
-
hypermethylated in invasive and in in situ lobular breast cancer
-
Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors
-
high in normal-1 (HIN-1) is downregulated in stage I non-small cell lung cancer
-
silencing of HIN-1 expression and methylation of its promoter occurs in multiple human cancer types, suggesting that elimination of HIN-1 function may contribute to several forms of epithelial tumorigenesis
-
Aberrant methylation of HIN-1 is a frequent event in many human malignancies
-
Studies provide further evidence that HIN-1 possesses tumor suppressor functions, and that these activities may be mediated through the AKT signaling pathway.
